Opinion
Video
Fred Saad, MD, on implications of phase 3 ARANOTE data in mHSPC
Author(s):
“We already have very effective ARPIs available around the world, and this will add to those therapeutic options to try to tailor patients based on their needs [and] their particular profiles,” says Fred Saad, MD, FRCS.
In this interview, Fred Saad, MD, FRCS discusses implications of findings from the study, “Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial,” which was presented at the 2024 European Society for Medical Oncology Annual Congress in Barcelona, Spain. Overall, results of the phase 3 ARANOTE study (NCT04736199) indicated that combination treatment with darolutamide (Nubeqa) plus ADT is associated with a significant reduction in the risk of radiological progression or death in men with mHSPC.
Saad is the director of Prostate Cancer Research at the Montreal Cancer Institute/University of Montreal Hospital Center (CHUM) Research Center (CRCHUM)and a professor of surgery at the University of Montreal in Quebec, Canada.
Video Transcript:
What are some of the potential clinical implications of these findings?
Obviously, what we hope is that this will become another standard of care for patients using what we consider now the best baseline standard of care for metastatic hormone-sensitive, which means ADT plus an ARPI. We already have very effective ARPIs available around the world, and this will add to those therapeutic options to try to tailor patients based on their needs [and] their particular profiles. But also, what's very nice is we already have the combination with docetaxel, so we'll be able to be considering patients ADT plus darolutamide plus or minus docetaxel based on patient needs and preference.
What future work is planned based on this study?
There are a lot of initiatives that are going on since the safety profile is very good [and] the efficacy is excellent. Looking at even earlier settings of the disease, prior to metastatic disease or metastatic hormone-sensitive disease, those are things that are in the works, and trials are ongoing. I think it's a very interesting drug to be able to look at combinations, since we're able to safely administer this with many drugs with little fear of worsening the side effect profiles of combinations, and the drug-drug interactions are really quite encouraging.
This transcription has been edited for clarity.
